Results 41 to 50 of about 3,844,628 (256)

Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents [version 2; referees: 2 approved]

F1000Research, 2016
Recent improvements have been made in the treatment of hepatitis C virus (HCV) infection with the introduction of direct-acting antiviral agents (DAAs).
Sara Kishta, Reem EI-Shenawy, Sobhy Kishta   +2 more
doaj   +1 more source

Evidence‐Based Clinical Practice Guidelines for the Management of Pediatric Febrile Neutropenia: Resource‐Sensitive Recommendations for the Asian Continent

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Febrile neutropenia (FN) is a frequent and serious complication in children receiving cancer therapy. Standardizing FN management across Asia is challenging due to variable healthcare infrastructure, diagnostic capacity, and infection patterns; however, it could improve resource use and patient outcomes.
Joliza Patricia Cañeba, Shweta Bansal, Tea Reljic, Allyne Montecillo‐Aguelo, Hamidah Alias, Farrah Amaranto, Maria Stella Aquino‐Calingasan, Bambang Ardianto, Eggi Arguni, Sally Blair, Thi Tam Dang, Maria Beatriz Gepte, Samanmalee Gunasekara, Andini Handayani, Miriam Kimpo, Catherine G. Lam, Nawachai Lertvivatpong, Sergio Licona, Ana Loseo, Ratha Mlis, Vivian Moreno Berrio, Nguyen Hoai Anh, Anna Lisa Ong‐Lim, Ha Thu Pham, Krishna Sagar Sharma, Bun Sereyleak, Sally Jane G. Velasco‐Aro, Su Yadana, Ambuj Kumar, Sheena Mukkada   +29 more
wiley   +1 more source

Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents [version 3; referees: 2 approved]

F1000Research, 2017
Recent improvements have been made in the treatment of hepatitis C virus (HCV) infection with the introduction of direct-acting antiviral agents (DAAs).
Sara Sobhy Kishta, Sobhy Ahmed Kishta, Reem El-Shenawy   +2 more
doaj   +1 more source

Distribution of direct-acting antiviral treatments and early treatment discontinuation by regimen.

, 2019
Distribution of direct-acting antiviral treatments and early treatment discontinuation by regimen.
David Muschi (7300049), Paul Y. Kwo (7300040), Amy Puenpatom (4800831), Siu L. Hui (7300043), Zuoyi Zhang (6874895), Andrea A. Kelley (7300046)   +5 more
core   +1 more source

PRISMA checklist for ‘Efficacy and Safety Direct Acting Antiviral (DAA) Treatment for Chronic Hepatitis C Infection in Liver Cirrhosis: A Systematic Review and Meta-Analysis’

, 2023
PRISMA checklist for systematic review and meta-analysis of "Efficacy and Safety Direct Acting Antiviral (DAA) Treatment for Chronic Hepatitis C Infection in Liver Cirrhosis: A Systematic Review and Meta-Analysis"
Ni Luh Putu Yunia Dewi (16458849)
core   +1 more source

Diversity and complexity in neural organoids

FEBS Letters, EarlyView.
Neural organoid research aims to expand genetic diversity on one side and increase tissue complexity on the other. Chimeroids integrate multiple donor genomes within single organoids. Self‐organising multi‐identity organoids, exogenous cell seeding, or enforced assembly of region‐specific organoids contribute to tissue complexity.
Ilaria Chiaradia, Madeline A. Lancaster
wiley   +1 more source

Sustained virologic response for all-oral direct acting antiviral regimens.

, 2015
+Interferon ineligible/intolerant;*24 weeks of treatment; GT1 (a/b), genotype-1; GT2, genotype-2; GT3, genotype-3; N/A, not availableSustained virologic response for all-oral direct acting antiviral regimens.
Susanna Naggie (304827), Stacy M. Horner (178713)   +1 more
core   +1 more source

HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. [PDF]

, 2013
UNLABELLED: Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is
Dillon, John, Hellard, M, Grebely, J ; https://orcid.org/, Hellard, Margaret, Goldberg, David J., Martin, Natasha K, Goldberg, DJ, Vickerman, P, Dore, Gregory J, Goldberg, David, Hickman, M ; https://orcid.org/, Hickman, Matthew, Lima, Viviane D, Grebely, J, Hutchinson, SJ, Dillon, John F.; id_orcid, Foster, Graham R., Lima, Viviane, Hickman, M, Martin, Natasha, Hutchinson, Sharon J.; id_orcid, Lima, VD, Martin, NK, Dore, Gregory J., Foster, Graham, Lima, Viviane D., Dore, Gregory, Vickerman, Peter, Goldberg, David J, Dillon, John F, Grebely, Jason, Hutchinson, Sharon, Hutchinson, Sharon J., Foster, Graham R, Dillon, JF, Dore, GJ ; https://orcid.org/, Foster, GR, Dillon, John F., Dore, GJ, Hutchinson, Sharon J, Martin, Natasha K.   +40 more
core   +1 more source

Direct-Acting Antiviral Agents and the Path to Interferon Independence [PDF]

Clinical Gastroenterology and Hepatology, 2014
Chronic infection with hepatitis C virus (HCV) is a major global health problem; there are approximately 120 to 130 million chronic infections worldwide. Since the discovery of HCV 24 years ago, there has been a relentless effort to develop successful antiviral therapies.
Warren N, Schmidt, David R, Nelson, Jean-Michel, Pawlotsky, Kenneth E, Sherman, David L, Thomas, Raymond T, Chung   +5 more
openaire   +2 more sources

Organizing the interface—Plasma membrane architecture and receptor dynamics in virus‐cell interactions

FEBS Letters, EarlyView.
Plasma membranes contain dynamic nanoscale domains that organize lipids and receptors. Because viruses operate at similar scales, this architecture shapes early infection steps, including attachment, receptor engagement, and entry. Using influenza A virus and HIV‐1 as examples, we highlight how receptor nanoclusters, multivalent glycan interactions ...
Jan Schlegel, Christian Sieben
wiley   +1 more source